| Scarlette D Smith, MD | |
|
1705 Main Ave Sw, Suite B, Cullman, AL 35055-7206 | |
| (256) 739-8260 | |
| (256) 739-8263 |
| Full Name | Scarlette D Smith |
|---|---|
| Gender | Female |
| Speciality | Dermatology |
| Experience | 34 Years |
| Location | 1705 Main Ave Sw, Cullman, Alabama |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1386636132 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | 15896 (Alabama) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Warehouse Primary Care And Specialty Clinic Inc. | 8527446301 | 10 |
News Archive
The time for ethical reflection is before experimentation begins, especially in the case of potential new methods for creating human embryos for research, according to bioethicists from Wake Forest University Baptist Medical Center and the Mayo Clinic in the spring issue of Ethics & Medicine.
Groundbreaking articles in current issues of Journal of Opioid Management, for the first time explore, in depth, the emergence of cannabinoid medicine, its challenges for health care providers and its potential benefits for patients.
Dr. Jung-Mo Ahn, associate professor of chemistry at The University of Texas at Dallas, has designed and synthesized a novel small molecule that might become a large weapon in the fight against prostate cancer.
New research shows that exposure to harmful chemicals and drugs during critical developmental periods early in life may actually "reprogram" the way certain genes respond to the female hormone estrogen. This genetic reprogramming may determine whether people with a genetic predisposition for a disease actually develop the disease.
In a paper published in today's online issue of the Journal of Alzheimer's Disease (DOI 10.3233/JAD-190772), TauRx has reported unexpected results of a pharmacokinetic analysis of the relationship between treatment dose, blood levels and pharmacological activity of the drug hydromethylthionine on the brain in over 1,000 patients with mild-to-moderate Alzheimer's disease.
› Verified 2 days ago
| Entity Name | Dermatology And Laser Of Alabama Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003901679 PECOS PAC ID: 6204931066 Enrollment ID: O20070424000108 |
News Archive
The time for ethical reflection is before experimentation begins, especially in the case of potential new methods for creating human embryos for research, according to bioethicists from Wake Forest University Baptist Medical Center and the Mayo Clinic in the spring issue of Ethics & Medicine.
Groundbreaking articles in current issues of Journal of Opioid Management, for the first time explore, in depth, the emergence of cannabinoid medicine, its challenges for health care providers and its potential benefits for patients.
Dr. Jung-Mo Ahn, associate professor of chemistry at The University of Texas at Dallas, has designed and synthesized a novel small molecule that might become a large weapon in the fight against prostate cancer.
New research shows that exposure to harmful chemicals and drugs during critical developmental periods early in life may actually "reprogram" the way certain genes respond to the female hormone estrogen. This genetic reprogramming may determine whether people with a genetic predisposition for a disease actually develop the disease.
In a paper published in today's online issue of the Journal of Alzheimer's Disease (DOI 10.3233/JAD-190772), TauRx has reported unexpected results of a pharmacokinetic analysis of the relationship between treatment dose, blood levels and pharmacological activity of the drug hydromethylthionine on the brain in over 1,000 patients with mild-to-moderate Alzheimer's disease.
› Verified 2 days ago
| Entity Name | Warehouse Primary Care & Specialty Clinic Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1851037923 PECOS PAC ID: 8527446301 Enrollment ID: O20220607001998 |
News Archive
The time for ethical reflection is before experimentation begins, especially in the case of potential new methods for creating human embryos for research, according to bioethicists from Wake Forest University Baptist Medical Center and the Mayo Clinic in the spring issue of Ethics & Medicine.
Groundbreaking articles in current issues of Journal of Opioid Management, for the first time explore, in depth, the emergence of cannabinoid medicine, its challenges for health care providers and its potential benefits for patients.
Dr. Jung-Mo Ahn, associate professor of chemistry at The University of Texas at Dallas, has designed and synthesized a novel small molecule that might become a large weapon in the fight against prostate cancer.
New research shows that exposure to harmful chemicals and drugs during critical developmental periods early in life may actually "reprogram" the way certain genes respond to the female hormone estrogen. This genetic reprogramming may determine whether people with a genetic predisposition for a disease actually develop the disease.
In a paper published in today's online issue of the Journal of Alzheimer's Disease (DOI 10.3233/JAD-190772), TauRx has reported unexpected results of a pharmacokinetic analysis of the relationship between treatment dose, blood levels and pharmacological activity of the drug hydromethylthionine on the brain in over 1,000 patients with mild-to-moderate Alzheimer's disease.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Scarlette D Smith, MD 1705 Main Ave Sw, Suite B, Cullman, AL 35055-7206 Ph: (256) 739-8260 | Scarlette D Smith, MD 1705 Main Ave Sw, Suite B, Cullman, AL 35055-7206 Ph: (256) 739-8260 |
News Archive
The time for ethical reflection is before experimentation begins, especially in the case of potential new methods for creating human embryos for research, according to bioethicists from Wake Forest University Baptist Medical Center and the Mayo Clinic in the spring issue of Ethics & Medicine.
Groundbreaking articles in current issues of Journal of Opioid Management, for the first time explore, in depth, the emergence of cannabinoid medicine, its challenges for health care providers and its potential benefits for patients.
Dr. Jung-Mo Ahn, associate professor of chemistry at The University of Texas at Dallas, has designed and synthesized a novel small molecule that might become a large weapon in the fight against prostate cancer.
New research shows that exposure to harmful chemicals and drugs during critical developmental periods early in life may actually "reprogram" the way certain genes respond to the female hormone estrogen. This genetic reprogramming may determine whether people with a genetic predisposition for a disease actually develop the disease.
In a paper published in today's online issue of the Journal of Alzheimer's Disease (DOI 10.3233/JAD-190772), TauRx has reported unexpected results of a pharmacokinetic analysis of the relationship between treatment dose, blood levels and pharmacological activity of the drug hydromethylthionine on the brain in over 1,000 patients with mild-to-moderate Alzheimer's disease.
› Verified 2 days ago
Dr. Clancy Hagedorn Johnson, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 1300 Bridge Creek Dr. Ne, Suite A, Cullman, AL 35055 Phone: 256-737-7546 Fax: 256-841-6180 | |
Steven Mark Skinner, M.D. Dermatology Medicare: Medicare Enrolled Practice Location: 1205 County Road 1466, Cullman, AL 35058 Phone: 256-739-9711 Fax: 256-739-9737 |